Pavel Strop PhD

Dr. Strop received his Ph.D. from Caltech, where he elucidated mechanism and structures of mechanosensitive ion channels. Afterward, he moved to Stanford, where he focused on proteins involved in synaptic neurotransmission. In 2008, he joined Rinat-Pfizer's protein engineering department where he developed and applied novel technologies for oncology including specifics and site-specific antibody-drug conjugates. In 2016, he joined Bristol-Myers Squibb in Redwood City, California where he focuses on engineering next-generation immuno-oncology therapeutics. Dr. Strop co-authored over 55 peer-reviewed manuscripts and 13 US patents.